La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ResMed Résultats passés
Passé contrôle des critères 5/6
ResMed has been growing earnings at an average annual rate of 16.7%, while the Medical Equipment industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 11.7% per year. ResMed's return on equity is 21%, and it has net margins of 21.8%.
Informations clés
16.7%
Taux de croissance des bénéfices
16.2%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.9% |
| Taux de croissance des recettes | 11.7% |
| Rendement des fonds propres | 21.0% |
| Marge nette | 21.8% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors
Apr 09A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Mar 26ResMed goes ex dividend tomorrow
Feb 07ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06Ventilation des recettes et des dépenses
Comment ResMed gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 4,685 | 1,021 | 917 | 308 |
| 31 Mar 24 | 4,584 | 958 | 916 | 305 |
| 31 Dec 23 | 4,504 | 890 | 914 | 304 |
| 30 Sep 23 | 4,375 | 907 | 903 | 300 |
| 30 Jun 23 | 4,223 | 898 | 874 | 288 |
| 31 Mar 23 | 4,016 | 863 | 826 | 274 |
| 31 Dec 22 | 3,763 | 809 | 780 | 264 |
| 30 Sep 22 | 3,624 | 786 | 755 | 257 |
| 30 Jun 22 | 3,578 | 779 | 738 | 254 |
| 31 Mar 22 | 3,539 | 779 | 726 | 249 |
| 31 Dec 21 | 3,444 | 522 | 704 | 238 |
| 30 Sep 21 | 3,349 | 500 | 688 | 231 |
| 30 Jun 21 | 3,197 | 475 | 670 | 225 |
| 31 Mar 21 | 3,091 | 457 | 654 | 218 |
| 31 Dec 20 | 3,092 | 699 | 666 | 213 |
| 30 Sep 20 | 3,028 | 680 | 668 | 208 |
| 30 Jun 20 | 2,957 | 622 | 677 | 202 |
| 31 Mar 20 | 2,892 | 513 | 683 | 201 |
| 31 Dec 19 | 2,784 | 455 | 675 | 197 |
| 30 Sep 19 | 2,699 | 419 | 665 | 190 |
| 30 Jun 19 | 2,607 | 405 | 645 | 181 |
| 31 Mar 19 | 2,525 | 446 | 630 | 169 |
| 31 Dec 18 | 2,455 | 450 | 614 | 159 |
| 30 Sep 18 | 2,405 | 335 | 604 | 157 |
| 30 Jun 18 | 2,340 | 316 | 600 | 155 |
| 31 Mar 18 | 2,273 | 307 | 591 | 152 |
| 31 Dec 17 | 2,196 | 285 | 581 | 150 |
| 30 Sep 17 | 2,125 | 352 | 569 | 147 |
| 30 Jun 17 | 2,067 | 342 | 554 | 144 |
| 31 Mar 17 | 2,029 | 324 | 532 | 142 |
| 31 Dec 16 | 1,968 | 327 | 518 | 135 |
| 30 Sep 16 | 1,893 | 346 | 496 | 126 |
| 30 Jun 16 | 1,839 | 352 | 488 | 119 |
| 31 Mar 16 | 1,773 | 357 | 481 | 113 |
| 31 Dec 15 | 1,742 | 357 | 475 | 112 |
| 30 Sep 15 | 1,710 | 353 | 479 | 112 |
| 30 Jun 15 | 1,679 | 353 | 479 | 115 |
| 31 Mar 15 | 1,641 | 353 | 478 | 118 |
| 31 Dec 14 | 1,616 | 352 | 473 | 121 |
| 30 Sep 14 | 1,578 | 348 | 466 | 121 |
| 30 Jun 14 | 1,555 | 345 | 450 | 118 |
| 31 Mar 14 | 1,554 | 331 | 443 | 118 |
| 31 Dec 13 | 1,540 | 325 | 441 | 119 |
| 30 Sep 13 | 1,532 | 317 | 434 | 120 |
Des revenus de qualité: RMD has high quality earnings.
Augmentation de la marge bénéficiaire: RMD's current net profit margins (21.8%) are higher than last year (21.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: RMD's earnings have grown by 16.7% per year over the past 5 years.
Accélération de la croissance: RMD's earnings growth over the past year (13.7%) is below its 5-year average (16.7% per year).
Bénéfices par rapport au secteur d'activité: RMD earnings growth over the past year (13.7%) exceeded the Medical Equipment industry 5.5%.
Rendement des fonds propres
ROE élevé: RMD's Return on Equity (21%) is considered high.